recent drug approv add growth potenti
receiv snda approv anlotinib sarcoma think could
becom standard second-lin treatment new sarcoma
patient china estim peak sale sarcoma reach
mn alreadi factor model
multipl potenti approv anlotinib new indic sbp
also submit snda anlotinib sclc conduct
trial escc/mtc/crc/npc see approv
indic unlock substanti market potenti
sbp gener franchis tadalafil ticagrelor recent
pass test estim could take
china ed/ticagrelor market peak sale
maintain neutral lift tp
increas revenu net profit
respect factor newli approv gener
estim net profit grow manag
guid net profit growth
approv anlotinib second-lin treatment sarcoma base
phase iib studi patient orr object respons
rate /dcr diseas control rate anlotinib-tr group reach
significantli higher
longer progress-fre surviv month anotinib vs
month control
sinc treatment option exist sarcoma china chemo
failur think anlotinib could becom standard second-lin
treatment new incid china estim
anlotinib peak sale sarcoma reach mn
alreadi factor model
besid sarcoma sbp submit snda anlotinib sclc
line cancer conduct addit trial escc
cancer npc nasopharyng carcinoma believ
subsequ approv indic would fulli unlock big
market potenti drug
figur anlotinib clinic registr statu updat
gener franchis sinc june tadalafil ticagrelor
pass bio-equival test think approv could
open substanti new revenu sourc sbp gener drug franchis
estimate pot chg tp
number share mn
chg prev ep
off-set potenti neg impact price cut gpo
long-act inhibitor treatment erectil
dysfunct ed benign prostat hyperplasia bph current
tadalafil sale lilli account
bn
chines ed market tadalafil gener enter market
afford price expect tadalafil could take ed
market china sbp second compani haiyu pass
test tadalafil could becom domin player market
strong sale forc take china ed market view
ticagrelor new gener receptor antagonist
demonstr significantli reduc death risk ac patient
clopidogrel current ticagrelor sale astrazeneca azn
mn china think market
educ price cut insur coverag ticagrelor could
becom mainstream drug platelet-aggreg diseas
expect sbp start sell ticagrelor azn patent
expir besid sbp salubri cspc also pass test
ticagrelor thu think sbp could take ticagrelor
market share peak sale
maintain neutral lift tp lift sbp
revenu net profit
newli approv gener expect
anlotinib sale reach bn well offset
sale reduct runzhong price cut estim
net profit grow manag guid net profit
growth maintain neutral sbp gener
still face price-cut pressur gpo nationwid expans
extens drug new tp base dcf
model assum wacc perpetu growth rate
factor
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau univers toronto compani mention price
serena shao fei zheng certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
price rate histori astrazeneca azn
signifi initi assumpt coverag
price rate histori cspc pharmaceut group ltd
signifi initi assumpt coverag
charl martineau univers toronto price rate histori co lli
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori shenzhen salubri pharmaceut co ltd
signifi initi assumpt coverag
price rate histori sino biopharmaceut limit
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
charl martineau univers toronto neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european rate base stock total return rel analyst coverag univers consist
compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun latin american asia stock exclud japan australia rate
base stock total return rel averag total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti current share price
rel attract stock total return potenti within analyst coverag univers australian new zealand stock
expect total return calcul includ roll dividend yield outperform rate assign greater
equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk prior may
rang outperform under-perform rate overlap neutral threshold oper
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
